ProCE Banner Activity

Experts Answer Questions on Personalized Management of Patients With Myelodysplastic Syndromes

Podcast Episodes

Listen as expert faculty answer audience questions on personalized management of patients with MDS from a live symposium during ASH 2022.

Released: February 17, 2023

Expiration: February 16, 2024

Share

Faculty

María Díez Campelo

María Díez Campelo, MD, PhD

Associate Professor
Department of Medicine
School of Medicine
University of Salamanca
Hematologist
Department of Hematology
University Hospital of Salamanca
Salamanca, Spain

Rami Komrokji

Rami Komrokji, MD

Section Head – Leukemia & MDS, Vice Chair
Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Amer Zeidan

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Bristol Myers Squibb

Geron

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

María Díez Campelo, MD, PhD

Associate Professor
Department of Medicine
School of Medicine
University of Salamanca
Hematologist
Department of Hematology
University Hospital of Salamanca
Salamanca, Spain

María Díez Campelo, MD, PhD: consultant/advisor/speaker: Blueprint, Bristol Myers Squibb, Novartis, Takeda.

Rami Komrokji, MD

Section Head – Leukemia & MDS, Vice Chair
Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Rami Komrokji, MD: consultant/advisor/speaker: AbbVie, Bristol-Myers Squibb, CTI BioPharma, Geron, Gilead Sciences, Jazz, Novartis, PharmaEssentia, Servier, Taiho, Takeda.

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Amer Zeidan, MBBS, MHS: researcher: AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, Boehringer Ingelheim, Cardiff Oncology, Celgene/Bristol-Myers Squibb, Incyte, Medimmune/AstraZeneca, Novartis, Otsuka, Pfizer, Takeda, Trovagene; consultant: Acceleron, Agios, Amgen, Aprea, Astellas, Astex, BeyondSpring, Boehringer Ingelheim, Cardiff Oncology, Celgene/Bristol-Myers Squibb, Cardinal Health, Daiichi Sankyo, Epizyme, Gilead Sciences, Incyte, Ionis, Janssen, Jazz, Kura, Novartis, Otsuka, Pfizer, Seattle Genetics, Syndax, Taiho, Takeda, Trovagene, Tyme.